Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.

Cardiovascular Drugs and Therapy
Azita H TalasazBabak Geraiely

Abstract

Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.

References

Aug 19, 2007·Journal of Cardiovascular Pharmacology·Mohan K Raizada, Anderson J Ferreira
Apr 2, 2013·Mayo Clinic Proceedings·Kristina H HaugaaMichael J Ackerman
May 30, 2013·Circulation. Cardiovascular Quality and Outcomes·James E TisdaleRichard J Kovacs
Jul 5, 2013·European Heart Journal·Alida L P CaforioUNKNOWN European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
Sep 25, 2017·American Journal of Physiology. Lung Cellular and Molecular Physiology·Chhinder P SodhiHongpeng Jia
Dec 26, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Connie B NewmanUNKNOWN American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the C
Mar 4, 2019·The Canadian Journal of Cardiology·Pierre GiguèreJonathan B Angel
Mar 23, 2019·Journal of the American College of Cardiology·Otavio BerwangerJose C Nicolau
Aug 15, 2019·Journal of Thrombosis and Haemostasis : JTH·Toshiaki IbaUNKNOWN Scientific and Standardization Committee on DIC, and the Scientific and Standardization Committee on Perioperative and Criti
Feb 8, 2020·JAMA : the Journal of the American Medical Association·Dawei WangZhiyong Peng
Feb 29, 2020·The New England Journal of Medicine·Wei-Jie GuanUNKNOWN China Medical Treatment Expert Group for Covid-19
Mar 7, 2020·Nature Reviews. Cardiology·Ying-Ying ZhengXiang Xie
Mar 15, 2020·Progress in Cardiovascular Diseases·Giuseppe LippiFabian Sanchis-Gomar
Mar 15, 2020·The Lancet. Respiratory Medicine·Lei FangMichael Roth
Mar 18, 2020·Clinica Chimica Acta; International Journal of Clinical Chemistry·Giuseppe LippiBrandon Michael Henry
Mar 19, 2020·European Heart Journal·Tian-Yuan XiongMao Chen
Mar 21, 2020·Journal of the American College of Cardiology·Barbara S WigginsTy J Gluckman
Mar 24, 2020·Journal of the American College of Cardiology·Elissa DrigginSahil A Parikh
Mar 29, 2020·JAMA Cardiology·Riccardo M InciardiMarco Metra
Apr 1, 2020·European Heart Journal·Gian Battista DanziElisa Gherbesi
Apr 4, 2020·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Cheng-I WuArthur A M Wilde
Apr 5, 2020·Diabetes & Metabolic Syndrome·Manish Bansal
Apr 9, 2020·The New England Journal of Medicine·Yan ZhangShuyang Zhang
Apr 11, 2020·European Journal of Heart Failure·Guido TavazziEloisa Arbustini
Apr 14, 2020·Journal of Cardiovascular Pharmacology·Dave L DixonAntonio Abbate
Apr 15, 2020·Circulation·Pietro Enea LazzeriniPier Leopoldo Capecchi
Apr 20, 2020·Journal of Vascular Surgery. Venous and Lymphatic Disorders·Andrea T ObiPeter K Henke
Apr 28, 2020·European Heart Journal Cardiovascular Imaging·Jean-François PaulChristelle Diakov
Apr 28, 2020·Journal of Thrombosis and Haemostasis : JTH·Jecko ThachilToshiaki Iba
Apr 28, 2020·Blood·Jean M Connors, Jerrold H Levy
Apr 30, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Kamalan Jeevaratnam
May 2, 2020·The New England Journal of Medicine·Mandeep R MehraAmit N Patel
May 2, 2020·The New England Journal of Medicine·Giuseppe ManciaGiovanni Corrao
May 2, 2020·The New England Journal of Medicine·Harmony R ReynoldsJudith S Hochman

❮ Previous
Next ❯

Citations

Nov 19, 2020·Therapeutics and Clinical Risk Management·Faeze Keihanian, Leila Bigdelu
Jun 29, 2021·Frontiers in Cell and Developmental Biology·Amirhesam BabajaniHassan Niknejad
Sep 4, 2021·The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology·Eman SobhHani A Alhadrami

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapies
pharmacotherapy

Software Mentioned

IMPROVE
Caprini

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Related Papers

The American Journal of the Medical Sciences
Wei-Ting ChangWen-Liang Yu
Current Cardiology Reports
Nicolas L PalaskasAnita Deswal
The Indian Journal of Medical Research
Yash Paul SharmaAnkur Gupta
The Indian Journal of Medical Research
Yash Paul SharmaAnkur Gupta
The American Journal of Emergency Medicine
Brit LongMichael Gottlieb
© 2021 Meta ULC. All rights reserved